Nootkatone
Catalog No: CFN98699
Nootkatone, a naturally occurring AMPK activator, can stimulate energy metabolism and prevents diet-induced obesity by activating AMPK. (+)-Nootkatone has antiallergic, anti-inflammatory, antiproliferative, and antiplatelet activities. Nootkatone is a strong repellent and toxicant to Formosan subterranean termites, the lowest effective concentration tested is 10 micrograms/g substrate. (+)-Nootkatone has potent inhibitory effect on collagen-, thrombin-, and AA-induced platelet aggregation, it also has a significant inhibitory effect on rat platelet aggregation ex vivo.
Isorhamnetin
Catalog No: CFN98735
Isorhamnetin, a natural flavonol aglycon, is a tyrosinase inhibitor and has anti-adipogenic, cardioprotective, anti-tumor, and antioxidant activities. it inhibits the H(2)O(2)-induced activation of the intrinsic apoptotic pathway via ROS scavenging and ERK inactivation, it inhibits NF-κB signaling. Isorhamnetin prevents angiotensin II (AngII)-induced endothelial dysfunction by inhibiting the overexpression of p47(phox) and the subsequent increases O2-production, resulting in increased nitric oxide bioavailability.
Theaflavin
Catalog No: CFN98597
Theaflavin is a suitable natural inhibitor against influenza A (H1N1) neuraminidase, which has anti-inflammatory, antioxidative, anti-mutagenic, anti-HSV-1, and anti-carcinogenic properties. Theaflavin is active in the prevention of fatty liver and obesity, it can significantly reduce lipid accumulation, suppress fatty acid synthesis, and stimulate fatty acid oxidation. Theaflavin inhibits LPS-Induced IL-6, MCP-1, and ICAM-1 expression in bone marrow-derived macrophages through the blockade of NF-κB and MAPK signaling pathways; it also protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.
Kirenol
Catalog No: CFN98867
Kirenol possesses anti-bacteria, immunosuppression, anti-obesity, anti-oxidant, anti-inflammatory, anti-allergic, and anti-arthritic activities. Kirenol has significant potential for its discovery as a new lead compound for management of topical pain and inflammation; it can upregulate nuclear Annexin-1 which interacts with NF-κB to attenuate synovial inflammation of collagen-induced arthritis in rats. Kirenol can attenuate experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells. Kirenol activates the BMP and Wnt/β-catenin signaling pathways.
